Skip to main content
OpenTrials

Clinical trial condition

Primary Immunodeficiency Diseases (PID)

Explore clinical trials studying Primary Immunodeficiency Diseases (PID). Study availability and eligibility vary by location and protocol.

24 public trials 2 recruiting studies
Refine in advanced search Browse all conditions

Primary Immunodeficiency Diseases (PID) trial results

Completed

Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects

NCT03277313

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • University of Alabama Medical Center Birmingham, Alabama, United States
  • Connecticut Children's Medical Center Hartford, Connecticut, United States
  • University of Miami Pediatric Allergy and Immunology Miami, Florida, United States
  • University of South Florida Physician Group St. Petersburg, Florida, United States
View all 19 locations
View Trial Details
Completed

Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects

NCT03116347

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Fakultni nemocnice Brno Odd. Detska klinika Brno, Czechia
  • Fakultní nemocnice Hradec Králové Nový Hradec Králové, Czechia
  • FN v Motole Interni klinika Prague, Czechia
  • Rigshospitalet Copenhagen, Denmark
View all 20 locations
View Trial Details
Completed

Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)

NCT02593188

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Kern Allergy Medical Clinic Bakersfield, California, United States
  • University of California Irvine Medical Center Irvine, California, United States
  • Riviera Allergy Medical Center Redondo Beach, California, United States
  • Capital Allergy & Respiratory Disease Center Sacramento, California, United States
View all 30 locations
View Trial Details
Completed

Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders

NCT00157079

Conditions
Autoimmune Diseases, Blood Coagulation Disorders, Blood Platelet Disorders, +30 more
Locations
  • Children´s Hospital Los Angeles Los Angeles, California, United States
  • Stanford University Medical Center Stanford, California, United States
  • 1st Allergy and Clinical Research Center Englewood, Colorado, United States
  • Allergy Associates of the Palm Beaches North Palm Beach, Florida, United States
View Trial Details
Completed

Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)

NCT00161993

Conditions
Agammaglobulinemia, Blood Protein Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +10 more
Locations
  • Tampere University Hospital Tampere, Finland
  • Turku University Central Hospital Turku, Finland
  • SU/Sahlgrenska Gothenburg, Sweden
  • University Hospital Lund Lund, Sweden
View Trial Details
Completed

Phase 2/3 Study of IGSC, 20% in PIDD

NCT01218438

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • University of California, Irvine Irvine, California, United States
  • IMMUNOe International Research Centers Centennial, Colorado, United States
  • Allergy Associates of the Palm Beaches North Palm Beach, Florida, United States
  • Emory University Atlanta, Georgia, United States
View all 18 locations
View Trial Details
Completed

Gammagard Liquid and rHuPH20 in PID

NCT00814320

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Cypress, California, United States
  • Irvine, California, United States
  • Los Angeles, California, United States
  • San Francisco, California, United States
View all 14 locations
View Trial Details
Completed

Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

NCT00546871

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Los Angeles, California, United States
  • Centennial, Colorado, United States
  • North Palm Beach, Florida, United States
  • Atlanta, Georgia, United States
View Trial Details
Completed

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

NCT01485796

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • University of California, Irvine Irvine, California, United States
  • IMMUNOe International Research Centers Thornton, Colorado, United States
  • Allergy Associates of the Palm Beaches, PA North Palm Beach, Florida, United States
  • LSU Health Sciences Center & Children´s Hospital New Orleans, Louisiana, United States
View Trial Details

Related conditions